Tranzone secures GSK deal

Published: 8-Dec-2011
Finance Logistics

Will store various products in Jebel Ali for distribution to the Gulf and Near East Region

Tranzone Logistics, a subsidiary of Saudia Arabia-based Banaja Holdings, is to store various products for GlaxoSmithKline in its new warehouse in Jebel Ali for distribution to the Gulf and Near East Region.

The deal was signed during the opening ceremony for Tranzone’s new facility.

GSK will occupy a major part of Tranzone’s warehouse, contributing approximately 25% of revenue in 2012.

Tranzone said GSK had demanded top-of-the-range facilities and back up to protect products at all times and in all circumstances. Emphasis had also been placed on physical security such as access control and fire prevention and process quality.

Tranzone’s state-of-the-art 3PL warehouse at JAFZA in Jebel Ali provides storage, inventory management, as well as purchasing and re-invoicing to the distributor, all at one convenient location. The firm says it is able to store pharmaceuticals in an ideal environment, and its integrated system better links principals with distributors, removes layers of inefficiency and cuts costs while improving service quality.

See more

You may also like

Manufacturing

Banaja takes majority stake in DEEF Pharmaceutical

Read more
Aims to expand and diversify DEEF facility in Saudi Arabia

Trending Articles

  1. Agarose Bead Technologies marks 25 years with $10m global expansion plan The Spanish agarose resin specialist will expand into the US and India, invest in scalable bioprocessing technologies and enhance sustainability across its European facilities to meet growing demand for advanced therapy purification
  2. MilliporeSigma to acquire JSR Life Sciences’ chromatography business, boosting Protein A purification capabilities The acquisition expands MilliporeSigma’s downstream bioprocessing portfolio with JSR’s Amsphere Protein A resin technology, enhancing efficiency and reliability in monoclonal antibody and therapeutic protein production
  3. MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
  4. Sharp Services invests $100m to expand global sterile and packaging capacity across US and Europe The investment will boost sterile fill/finish, injectable packaging and oral solid dose capacity across Sharp's US and European sites, strengthening its clinical and commercial manufacturing network to meet growing pharmaceutical demand
  5. Novo Nordisk acquires rights to Omeros’ MASP-3 inhibitor zaltenibart in $2.1bn deal The agreement grants Novo Nordisk exclusive global rights to develop and commercialise the clinical-stage antibody for rare blood and kidney disorders, strengthening its Rare Disease portfolio

You may also like

Manufacturing

Banaja takes majority stake in DEEF Pharmaceutical

Aims to expand and diversify DEEF facility in Saudi Arabia
Finance

Shilpa Medicare opens flow chemistry manufacturing centre

The flow chemistry centre of excellence includes more than 100 R&D and manufacturing scientists
Finance

Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience

Cambrex's continued investments underscore its commitment to adding capabilities and increasing capacity to meet the evolving needs and growing demand of the pharmaceutical industry.
Finance

Curia invests $4m to enhance sterile API manufacturing

The investment aligns with the latest EU GMP Annex 1 standards and reinforces Curia’s longstanding commitment to regulatory excellence and product quality
Finance

Agarose Bead Technologies marks 25 years with $10m global expansion plan

The Spanish agarose resin specialist will expand into the US and India, invest in scalable bioprocessing technologies and enhance sustainability across its European facilities to meet growing demand for advanced therapy purification
Packaging

Sharp Services invests $100m to expand global sterile and packaging capacity across US and Europe

The investment will boost sterile fill/finish, injectable packaging and oral solid dose capacity across Sharp's US and European sites, strengthening its clinical and commercial manufacturing network to meet growing pharmaceutical demand
Finance

MilliporeSigma to acquire JSR Life Sciences’ chromatography business, boosting Protein A purification capabilities

The acquisition expands MilliporeSigma’s downstream bioprocessing portfolio with JSR’s Amsphere Protein A resin technology, enhancing efficiency and reliability in monoclonal antibody and therapeutic protein production
Subscribe now